Key result
Fixed-dose telmisartan/HCTZ lowers blood pressure more than separate components and provides organ protection.
Why the study?
Does a fixed combination of telmisartan and hydrochlorothiazide improve blood pressure reduction in patients with arterial hypertension compared to monotherapy?
Does a fixed combination of telmisartan and hydrochlorothiazide improve blood pressure reduction in patients with arterial hypertension compared to monotherapy?
Fixed-dose combination of telmisartan and hydrochlorothiazide is an effective strategy for managing arterial hypertension and providing organ protection.
May support fixed-dose telmisartan-hydrochlorothiazide in hypertension; leaves open randomized confirmation of organ protection.
Arterial hypertension (AH) remains one of the most prevalent cardiovascular disorder in the world, as one of the main risk factors of myocardial infarction and stroke development. Monotherapy of AH is effective in no more than one half of patients even with moderate increase of blood pressure. Combinational antihypertension treatment does influence pathogenetic mechanisms of AH being an optimal solution. It is worthful to apply a fixed combination of telmisartan and hydrochlorothiazide. Such combination provides additional antihypertensive effect with more significant decrease of blood pressure than for the components separately. Also it is protective for organs and tissues that makes it to prescribe such combination to a broad range of patients.
No takes yet. Share an insight, caveat, or question.
Подзолков et al. (2018) conducted a review in Arterial hypertension. Fixed combination of telmisartan and hydrochlorothiazide vs. Monotherapy or separate components was evaluated. A fixed combination of telmisartan and hydrochlorothiazide provides a more significant decrease in blood pressure than its separate components and offers organ protection in arterial hypertension.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: